Focused On-demand Library for Carbohydrate sulfotransferase 6

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9GZX3

UPID:

CHST6_HUMAN

Alternative names:

Corneal N-acetylglucosamine-6-O-sulfotransferase; Galactose/N-acetylglucosamine/N-acetylglucosamine 6-O-sulfotransferase 4-beta; N-acetylglucosamine 6-O-sulfotransferase 5

Alternative UPACC:

Q9GZX3; D3DUK3

Background:

Carbohydrate sulfotransferase 6, also known as Corneal N-acetylglucosamine-6-O-sulfotransferase, plays a pivotal role in the biosynthesis of keratan sulfate in the cornea. This enzyme is essential for the sulfation of non-reducing N-acetylglucosamine residues within keratan, contributing to corneal transparency and proteoglycan fibril organization. Its activity involves cooperation with B4GALT4 galactosyltransferase and B3GNT7 N-acetylglucosaminyltransferase.

Therapeutic significance:

Carbohydrate sulfotransferase 6 is directly implicated in Macular dystrophy, corneal, a disease characterized by corneal opacification and reduced sensitivity. Understanding the enzyme's role could lead to novel therapeutic strategies for this ocular disease, especially considering the genetic variants affecting its function.